42nd Annual General Meeting of the Shareholders of the Company is scheduled to be held on Tuesday, August 4, 2026
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong FY2025-26 results with consolidated revenue from operations growing 37% to Rs.2,02,299 lakhs from Rs.1,47,684 lakhs in the prior year. Profit after tax increased 40% to Rs.3,640 lakhs on consolidated basis, with EPS rising to Rs.283.71 from Rs.202.74. The Board recommended a final dividend of Rs.34 per equity share (340% on face value). An exceptional gain of Rs.7,640.36 lakhs from transfer of investment property was recorded. The company also approved appointment of Dr. Mauricio Futran as Additional Director and announced a Rs.143.4 crore capacity expansion at Unit 1 (adding 120.5 KL over 12-18 months) to meet growing customer demand. Statutory auditors issued an unmodified (clean) opinion on the financial statements.
Strong financial performance with robust revenue and profit growth, clean audit opinion, and capacity expansion signal positive momentum for the stock. The dividend payout of Rs.34 per share provides direct shareholder returns.